This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Macrolides in asthma

  • Research type

    Research Study

  • Full title

    Effect of macrolides on asthma control, airways inflammation and bacterial colonisation in smokers with asthma.

  • IRAS ID

    13980

  • Contact name

    Neil C. Thomson

  • Contact email

    n.c.thomson@clinmed.gla.ac.uk

  • Sponsor organisation

    Greater Glasgow & Clyde NHS and Glasgow University

  • Eudract number

    2008-007240-34

  • Clinicaltrials.gov Identifier

    00852579

  • Research summary

    Asthma is a common disease in Westernised societies, affecting up to 10% of the population. Steroids are the most effective treatment for asthma but not all patients obtain benefit. A major cause of steroidinsensitivity in asthma is cigarette smoking. New drugs are needed for smokers with asthma who are unable to stop smoking.Recent cellular and animal research as well as clinical studies in non-smokers with asthma has shown that a group of antibiotics called macrolides may improve asthma control in smokers with asthma by reducing airway inflammation, by restoring steroid sensitivity and/or by anti-bacterial effects.We plan a ??proof of concept?? study to determine the benificial effects of macrolides in smokers withasthma. The study will be a 12-week controlled clinical trial comparing the oral macrolide, azithromycin with a matched placebo. A total of 80 smokers with asthma will be recruited. We will study the effects of azithromycin on lung function, symptoms, airway inflammation and number of bacterial in sputum.This study will determine the benefits of macrolides as a new therapy for smokers with asthma.

  • REC name

    West of Scotland REC 1

  • REC reference

    09/S0703/23

  • Date of REC Opinion

    9 Feb 2009

  • REC opinion

    Favourable Opinion